Antibacterial efficacy of silver nanoparticles (AgNPs) against metallo-β-lactamase and extended spectrum β-lactamase producing clinically procured isolates of Pseudomonas aeruginosa.

Resistance to carbapenems is a global threat, especially in developing countries with limited health resources. Prevalence, antibiogram, PCR detection of antibiotic resistance genes, and potency of Silver Nanoparticles (AgNPs) against multidrug-resistant (MDR) Pseudomonas aeruginosa were studied. Kirby-Bauer disc method and PCR were used to study antibiogram and drug resistance genes respectively in 255 isolates of Pseudomonas aeruginosa obtained from a tertiary care hospital.

Successful outcome using Tocilizumab in COVID-19 pneumonia with respiratory failure on a ward level.

We describe the case of a 40-year-old man of Asian ethnicity, who presented with one week history of shortness of breath, productive cough, intermittent hemoptysis, temperature, and systemic symptoms. He had a positive nasopharyngeal swab for SARS-CoV-2, standard COVID panel admission blood tests, a chest X-ray and a CT Pulmonary Angiogram. Significant bilateral infiltrates and no pulmonary embolism were identified.

Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomial .

Objectives: Isolates producing metallo-β-lactamase (MBL) have a significant impact on therapeutic and diagnostic layouts, plus their increased frequency has been reported globally. Determination of incidence of clinical isolates of that are capable of producing MBL and AmpC-β-lactamases making them resistant to imipenem and cefoxitin.

Materials And Methods: Out of 1159 collected samples of urine, wound swabs, blood, tissue, and pus, the isolation rate of in the period of March 2020 to February 2021 was 22.